Ultragenyx Pharmaceutical, Inc. (RARE)
24.19
-0.81
(-3.24%)
USD |
NASDAQ |
May 18, 16:00
24.18
-0.02
(-0.06%)
After-Hours: 20:00
Ultragenyx Pharmaceutical Research and Development Expense (Quarterly) : 179.00M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Catalyst Pharmaceuticals, Inc. | 2.661M |
| BioMarin Pharmaceutical, Inc. | 178.80M |
| Regeneron Pharmaceuticals, Inc. | 1.420B |
| Xencor, Inc. | 64.67M |
| REGENXBIO, Inc. | 53.48M |